reported a high expression in 40% of carcinoid samples (31); however, the authors included 20 low-grade NE neoplasms without specifying the TC and AC proportion, nor the DLL3 immunohistochemical expression cutoff used. The gene discussed is DLL3; the disease is carcinoid tumor.